KalVista Pharmaceuticals (KALV) Misses Q2 EPS by 4c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.80), $0.04 worse than the analyst estimate of ($0.76).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• GameStop posts higher income despite revenue drop in Q2 2026
• T. Rowe Price (TROW) PT Raised to $110 at TD Cowen